IKT
NASDAQInhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc. (IKT) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for IKT, including 2 insider trades, 1 analyst rating and 1 leadership change. The most recent was published Oct 27, 2026.
News · 26 weeks38+500%
2026-05-102026-11-01
Mix1590d
- SEC Filings6(40%)
- Other5(33%)
- Insider2(13%)
- Analyst1(7%)
- Leadership1(7%)
Latest news
25 items- PRInhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today announced that the Company’s management will be participating in the following investor conferences during the month of November and December 2026. Jefferies Global Healthcare ConferenceNovember 16–19, 2026London, United KingdomPresentation Details: Fireside Chat with Mark Iwicki, CEO of Inhibikase and Dennis Ding, Jefferies Research on Monday, November 16 at 3:00pm (GMT)Meeting Details: one-on-one meetings on Monda
- INSIDERSEC Form 4 filed by Inhibikase Therapeutics Inc.4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERSEC Form 3 filed by Inhibikase Therapeutics Inc.3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Appoints Scott Wasserman to Board of DirectorsWILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s appointment, the Company also announced the resignation of Dennis Berman from the Company’s Board. "We thank Dennis for his many contributions to the Company during his years of service," said Amit Munshi, Chair of the Inhibikase Board of Directors. Dr. Wasserman is c
- ANALYSTChardan Capital Markets initiated coverage on Inhibikase Therapeutics with a new price targetChardan Capital Markets initiated coverage of Inhibikase Therapeutics with a rating of Neutral and set a new price target of $1.50
- PRInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of the Company’s common stock to two newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the "Inducement Plan"), effective as of September 30, 2026 (the "Effective Date"). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
- SECInhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECSEC Form S-8 filed by Inhibikase Therapeutics Inc.S-8 - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form 10-Q filed by Inhibikase Therapeutics Inc.10-Q - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent ActivityWILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments. "During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries," said Mark Iwicki, Chief Executive Officer of Inhibikase. "Also, during the quarter, favorable
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibikase Therapeutics Inc.SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- INSIDERLarge owner Ra Capital Management, L.P. disposed of 18,030,000 shares (SEC Form 4)4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- INSIDERDirector Berman Dennis N exercised 21,854 shares at a strike of $1.26 (SEC Form 4)4 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- SECInhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAHWILMINGTON, Del., July 23, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to its lead product candidate IKT-001, a prodrug of imatinib mesylate, for the treatment of PAH. "The grant of Orphan Drug Designation for IKT-001 by FDA is another important milestone for Inhibikase and reflects the high unmet medical need among the approximately 50,000 people suffering from PAH in the United States," said Mark Iwicki, Chief Executive
- INSIDERNew insider Ra Capital Management, L.P. claimed ownership of 25,000,000 shares (SEC Form 3)3 - Inhibikase Therapeutics, Inc. (0001750149) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Inhibikase Therapeutics Inc.SCHEDULE 13G - Inhibikase Therapeutics, Inc. (0001750149) (Subject)
- SECSEC Form 8-K filed by Inhibikase Therapeutics Inc.8-K - Inhibikase Therapeutics, Inc. (0001750149) (Filer)
- PRInhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) FacilityWILMINGTON, Del., July 14, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension ("PAH"), today announced that it has sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its at-the-market ("ATM") facility for gross proceeds of $50 million. The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in Part B of the Company’s ongoing global Phase 3 IMPROVE-PAH clinical study, subject to the full exercise of the o
IKT FAQ
8 questionsWhat does Inhibikase Therapeutics Inc. do?
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects...What is the latest news on IKT?
In the last 30 days Quantisnow tracked 6 wire items for IKT: 2 insider trades, 1 analyst rating, 1 leadership change and 1 SEC filing. The most recent was published on October 27, 2026.Where does IKT stock trade?
Inhibikase Therapeutics Inc. (IKT) is listed on NASDAQ.What sector and industry is IKT in?
Inhibikase Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Inhibikase Therapeutics Inc. go public?
Inhibikase Therapeutics Inc. (IKT) completed its IPO in 2020.What are analysts saying about IKT?
Across the last 8 analyst actions on Inhibikase Therapeutics Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Chardan Capital Markets: Neutral with a $1.50 price target on 2026-10-13.What companies are similar to IKT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IKT side-by-side with any of them on Quantisnow.How can I track IKT on Quantisnow?
Quantisnow aggregates Inhibikase Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IKT to receive live email and push alerts on every new disclosure.